Hormone Replacement Therapy Market will be around US$ 26.80 Billion by 2027 | Renub Research - Takeneasy.com

According to Renub Research, Hormone Replacement Therapy Market will experience a CAGR of 6.82% from 2022 to 2027. Hormone replacement therapy (HRT) is a medical treatment that can supplement or replace hormones that are no longer produced in sufficient quantities by the body. There is an increasing awareness of postmenopausal issues among women. Hence, there has been a surge in drug development with new delivery systems to address hormonal imbalance disorders, particularly in the growing senior population. The United Nations World Population Prospects 2022 report for the United States estimates that the global population will reach around 8.5 billion by 2030, 9.7 billion by 2050, and 10.4 billion by 2100.

HRT can alleviate menopausal symptoms, improve bone density, reduce the risk of osteoporosis and colon cancer, and help mood and cognitive function in some women. It may also reduce the risk of heart disease in younger women experiencing early menopause. However, suitability varies, and consulting with a healthcare provider is crucial due to potential side effects and health risks.

Demand for Menopausal Symptom Relief has boosted the Estrogen type in the HRT Industry

Estrogen is crucial for women during menopause, and its decline can cause hot flashes, night sweats, and vaginal dryness. The American Congress of Obstetricians and Gynecologists published a report saying that approximately 6,000 women in the United States experience menopause daily. Therefore, estrogen replacement therapy has become a standard treatment option.

In addition, drug development and delivery system advancements have led to new, safer, and more effective estrogen-based HRT formulations. Additionally, the growing geriatric population has contributed to the growth in the HRT industry, as menopause is more prevalent with age. This trend shall progress in the future.

Request a free sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=hormone-replacement-therapy-market-p.php

Oral Administration Convenience and Ease of use have made it dominant in the HRT Industry

The wide usage of Oral HRT is due to its convenience, safety profile, and availability in various dosages. Still, it may only suit some due to potential side effects and interactions. Therefore, alternative administration methods, such as transdermal or vaginal, may be considered for those who cannot tolerate or prefer not to take oral HRT.

Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=hormone-replacement-therapy-market-p.php

Asia-Pacific Aging Population has Boosted demand for HRT due to Increased Menopause-related Symptoms among Women

The HRT industry in the Asia-Pacific region has grown due to healthcare professionals and patients being more aware and accepting of HRT. There is also more accessible access to advanced medical facilities and healthcare services, thanks to rising disposable income and urbanization. As a result, HRT treatments are more accessible and affordable. Furthermore, the increasing prevalence of lifestyle-related diseases has driven the demand for HRT products to prevent and treat such conditions.

For instance, by 2030, one-fourth of older women in Korea will be postmenopausal. Furthermore, nearly half of all females will be postmenopausal, meaning that the percentage of postmenopausal women in the total female population will increase by 59.8% by 2060, according to an article titled “The Demographic Changes of Menopausal and Geripausal Women in Korea,” published in February 2021. To treat menopausal symptoms during this transition, healthcare professionals typically recommend a combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT).

Recent Developments

· In June 2022, Astellas Pharma Inc. submitted an NDA to the FDA for fezolinetant, an investigational nonhormonal oral compound for treating moderate to severe vasomotor symptoms (VMS) associated with menopause. These symptoms, including hot flashes and night sweats, are common during menopause. Fezolinetant is being considered a non-hormonal option for menopausal symptom relief.

· Pfizer Inc. 2022 finished obtaining Arena Pharmaceuticals. This obtaining will prompt an upgrade in a portfolio to dermatology, cardiology, gastroenterology, etc.

Type Outlook: Market has been covered from 5 viewpoints

1. Estrogen

2. Progesterone

3. Human Growth

4. Thyroid

5. Testosterone

Regional Outlook: Market has been covered from 5 viewpoints

1. North America

2. Europe

3. Asia Pacific

4. South America

5. Middle East Africa

Key Players Analysis

1. Merck KgaA

2. Bayer AG

3. Pfizer Inc.

4. Abbott Laboratories

5. Novartis AG

6. Novo Nordisk A/S

7. Amgen, Inc.

8. F. Hoffmann-La Roche

9. Eli Lilly and Company

About the Company:

Renub Research is a Market Research and Consulting Company. We have more than 10 years of experience especially in international Business-to-Business Researches, Surveys and Consulting. We provide a wide range of business research solutions that helps companies in making better business decisions. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses. Our wide clientele comprises major players in Healthcare, Travel and Tourism, Food Beverages, Power Energy, Information Technology, Telecom Internet, Chemical, Logistics Automotive, Consumer Goods Retail, Building, and Construction, Agriculture. Our core team is comprised of experienced people holding graduate, postgraduate, and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science, and many more.